Overview

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

Status:
Completed
Trial end date:
2020-08-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and it's objective is to monitor patients for approximately 8 years.
Details
Lead Sponsor:
UCB Pharma
Treatments:
Certolizumab Pegol